Monday, Shire laid out its justification for staying independent, eager to ward off circling suitors. Now, AbbVie, which has already made three passes at the Irish drugmaker, has laid out its own case for a takeover.
written on 25.06.2014
AbbVie can argue for a Shire buy, but price is the thing–and $51B might do it
